DV
Dividend Vision

TVTX — Travere Therapeutics, Inc.

Travere Therapeutics, Inc. (TVTX)

Total return is -89.4% over the past 23 years, 1183.5 points behind SPY at 1094.1%. Its deepest 1-year drawdown was 33.5%.

Travere Therapeutics is a biopharmaceutical company focused on developing and delivering therapies for rare kidney and metabolic diseases. The company markets FILSPARI for IgA Nephropathy and Thiola/Thiola EC for cystinuria, with additional clinical-stage programs in development for focal segmental glomerulosclerosis and classical homocystinuria. As an operating biopharmaceutical company, it does not have a distribution rate or yield profile, making it relevant primarily to growth-oriented investors rather than those seeking income.

TVTX key facts

Asset type
Stock
Asset class
Equity
Inception date
08/13/2003
Distribution frequency
None
Last close
$62.14
Market cap
$5,857,383,424
Average volume
1190600.0
Beta
1.042
Payout ratio
0.0
Forward P/E
76.3359
EPS
$-0.74